Clinical trials: IBS - Irritable Bowel Syndrome
Diarrhea Predominant Irritable Bowel Syndrome
Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D
Will Ranolazine improve bowel function and abdominal pain in human subjects with IBS-D?
- Trial name
- Ranolazine (NCT02239926)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome Characterized by Constipation
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
- Trial name
- NCT03573908
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 614 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The objectives of this study are to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide (DR; DR formulation 1 is DR1; DR formulation 2 is DR2) administered orally to patients with…
- Trial name
- NCT02559206
- Testing
- Linaclotide
- Where
- 71 sites in United States
- Volunteers
- 759 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome Characterized by Constipation
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
- Trial name
- IBS-C (NCT02493452)
- Testing
- Plecanatide
- Where
- 191 sites in United States
- Volunteers
- 1,135 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation Predominant Irritable Bowel Syndrome
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III…
- Trial name
- NCT01923428
- Testing
- AZD1722
- Where
- 4 sites in United States
- Volunteers
- 356 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome, Diarrhea
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
Our hypothesis is that the medication approved for treatment of high blood cholesterol levels, Colesevelam HCl (WELCHOL), decreases colonic transit and permeability in patients with diarrhea due to irritable bowel syndrome.
- Trial name
- welchol (NCT00911612)
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Fecal Incontinence, Irritable Bowel Syndrome With Diarrhea
The Role of Fiber in the Prevention and Treatment of Fecal Incontinence
The purpose of this study is to determine the effect of fiber supplementation on the fecal metagenome and metabolome in relation to symptoms and anorectal physiology in post-menopausal women with irritable bowel syndrome with…
- Trial name
- NCT04806386
- Testing
- Psyllium
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
Diarrhea Predominant Irritable Bowel Syndrome
Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
The purposes of this study are to prospectively determine the effect of a very low carbohydrate diet on quality of life and gastrointestinal symptoms in patients with diarrhea-predominant irritable bowel syndrome (IBS-D); and to…
- Trial name
- NCT00616200
- Testing
- Very low carbohydrate diet
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Irritable Bowel Syndrome, Constipation
Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or discomfort in association with altered bowel habit.
- Trial name
- NCT01162863
- Testing
- Lubiprostone, Smartpill wireless motility capsule
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan
Crohn's Disease
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
- Trial name
- NCT01199302
- Testing
- Brodalumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Amgen
Constipation Predominant Irritable Bowel Syndrome
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for…
- Trial name
- NCT01340053
- Testing
- RDX5791
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Ardelyx
IBS - Irritable Bowel Syndrome
Sex Differences in Effectiveness of CBT on IBS Project 3
Cognitive Behavioral Therapy (CBT) is the most well researched and most effective treatment for IBS targeting the brain-gut-microbiome (BGM) axis, and preliminary data show that this therapeutic effect is associated with a…
- Trial name
- U54_P3_CBT (NCT05155631)
- Testing
- COGNITIVE BEHAVIORAL THERAPY
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Irritable Bowel Syndrome Characterized by Constipation
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
- Trial name
- NCT02837783
- Testing
- Linaclotide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome, Abdominal Pain
Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study
This is a pilot study to compare the relative bioavailability between two peppermint oil formulations, namely a ileocolonic release peppermint oil and an small intestinal release peppermint oil (Tempocol®).
- Conditions
- Irritable Bowel Syndrome, Abdominal Pain, Colonic Diseases, Visceral Pain
- Trial name
- NCT02291445
- Testing
- Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule), Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
IBS - Irritable Bowel Syndrome
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
The purpose of this study is to study the relationship between the bile acids, short chain fatty acids and bacteria within the intestines.
- Trial name
- NCT03983434
- Testing
- Inulin
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Indiana University
Irritable Bowel Syndrome
Citalopram in Irritable Bowel Syndrome
Hypotheses: 1. Primary null hypothesis: The rate of clinical response, assessed as patient-reported global symptom rating and "adequate relief of IBS symptoms," does not differ between non-depressed IBS patients treated with the…
- Trial name
- NCT00477165
- Testing
- Citalopram
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Stanford University
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation
- Trial name
- NCT02493036
- Testing
- SYN-010
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome, Ulcerative Colitis
Efficacy of Gralise® for Chronic Pelvic Pain
This study is done to investigate the pain relieving effects of the study drug Gralise (a novel long acting gabapentinoid) for people who experience chronic pelvic pain.
- Conditions
- Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis
- Trial name
- NCT01678911
- Testing
- Gralise
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shirley Ryan AbilityLab